Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: A randomised trial

Lancet

Volumn 357, Issue 9258, 2001, Pages 739-745

  Toner, G C ^a   Stockler, M R ^b   Boyer, M J ^c   Jones, M ^b   Thomson, D B ^d   Harvey, V J ^e   Olver, I N ^f   Dhillon, H ^b   McMullen, A ^b   Gebski, V J ^b   Levi, J A ^g   Simes, R J ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEMINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0035836014     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04165-9     Document Type: Article

References (26)

1. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995
2. Incidence of testicular germ-cell malignancies in England and Wales: Trends in children compared with adults
3. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture
4. The role of maintenance therapy in disseminated testicular cancer
5. A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumors
6. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience
7. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)
8. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
9. Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors
10. Assessment of risk in metastatic testis carcinoma: Impact on treatment
11. Bleomycin in germ cell tumor therapy: Not all regimens are created equal
12. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma
13. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol
14. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial
15. Extragonadal and poor risk nonseminomatous germ cell tumors: Survival and prognostic features
16. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
17. Dynamic balancing for clinical trials
18. Reporting results of cancer treatment
19. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
20. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies
21. Stopping rules and estimation problems in clinical trials
22. Is 3BEP equivalent to 3BEP-1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study
23. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
24. Final analysis demonstrating the equivalence of 3 BEP vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III study
25. Two-drug therapy in patients with metastatic germ cell tumors
26. Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients with good-risk metastatic non seminomatous germ cell tumours? Preliminary results of a randomized trial